Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure

Inclusion Criteria: * Iron deficient subjects with stable chronic heart failure (CHF) (NYHA II-III) on optimal background therapy for CHF * Reduced exercise capacity * Reduced left ventricular ejection fraction * At least 18 years of age and with written informed consent prior to any study specific procedures Exclusion Criteria: * Erythropoietin stimulating agent (ESA) use, IV iron therapy, and/or blood transfusion in previous 6 weeks prior to randomisation * Exercise training program(s) in the 3 months prior to screening or planned in the next 6 months * Chronic liver disease and/or elevated liver enzymes * Vitamin B12 and/or serum folate deficiency * Subject is not using adequate contraceptive precautions during the study * No other significant cardiac or general disorder that would compromise participation in the study